Skip to main content
. 2020 Aug 5;63(10):2177–2181. doi: 10.1007/s00125-020-05227-z

Fig. 1.

Fig. 1

Estimated treatment effect ratio (C-peptide retention; active vs placebo) at 15 months post baseline in patients with or without genotypes that include HLA-DR3-DQ2 (n = 266 and 255), or HLA-DR3-DQ2 but not HLA-DR4-DQ8 (n = 127 and n = 394). Adjusted p values using the Bonferroni- Šidák correction are reported along with two-sided 95% CIs